TY - JOUR
T1 - Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients
AU - Valdez, Clarissa
AU - Wong, Yvette C.
AU - Schwake, Michael
AU - Bu, Guojun
AU - Wszolek, Zbigniew K.
AU - Krainc, Dimitri
N1 - Funding Information:
We thank Dr. Taiji Tsunemi for his thoughtful advice and guidance. We are grateful to Maria Nguyen, Hyunkyung Jeong and Drs. Jessica McDonald and Niccolo Mencacci for valuable discussions and technical expertise. We thank Dr. Evangelos Kiskinis for his advise and technical expertise on cortical neuron differentiation and Dr. Anis Contractor for generously donating the constructs used for the differentiation. We thank Lennell Reynolds Jr. for EM assistance, and Paul Mehl for FACs assistance.National Institutes of Health grants [R01 NS076054 and R37 NS096241 to D.K.], [5R25 GM079300-07 and 5T32 AG020506-13 to C.V], [T32 NS041234 and F32 NS101778 to Y.C.W.] and [P50 NS072187 to Z.W.], Human Embryonic and Induced Pluripotent Stem Cell Facility at Northwestern University (NIH core support grant P30 [NS081774]), Northwestern University Flow Cytometry Core (supported by NCI CCSG P30 [CA060553] awarded to the Robert H Lurie Comprehensive Cancer Center), Northwestern University Center for Advanced Microscopy (supported by NCI CCSG P30 [CA060553] awarded to the Robert H Lurie Comprehensive Cancer Center) and Mayo Clinic Center for Regenerative Medicine
Publisher Copyright:
© The Author 2017. Published by Oxford University Press.
PY - 2017/12
Y1 - 2017/12
N2 - Frontotemporal dementia (FTD) encompasses a group of neurodegenerative disorders characterized by cognitive and behavioral impairments. Heterozygous mutations in progranulin (PGRN) cause familial FTD and result in decreased PGRN expression, while homozygous mutations result in complete loss of PGRN expression and lead to the neurodegenerative lysosomal storage disorder neuronal ceroid lipofuscinosis (NCL). However, how dose-dependent PGRN mutations contribute to these two different diseases is not well understood. Using iPSC-derived human cortical neurons from FTD patients harboring PGRN mutations, we demonstrate that PGRN mutant neurons exhibit decreased nuclear TDP-43 and increased insoluble TDP-43, as well as enlarged electron-dense vesicles, lipofuscin accumulation, fingerprint-like profiles and granular osmiophilic deposits, suggesting that both FTD and NCL-like pathology are present in PGRN patient neurons as compared to isogenic controls. PGRN mutant neurons also show impaired lysosomal proteolysis and decreased activity of the lysosomal enzyme cathepsin D. Furthermore, we find that PGRN interacts with cathepsin D, and that PGRN increases the activity of cathepsin D but not cathepsins B or L. Finally, we show that granulin E, a cleavage product of PGRN, is sufficient to increase cathepsin D activity. This functional relationship between PGRN and cathepsin D provides a possible explanation for overlapping NCL-like pathology observed in patients with mutations in PGRN or CTSD, the gene encoding cathepsin D. Together, our work identifies PGRN as an activator of lysosomal cathepsin D activity, and suggests that decreased cathepsin D activity due to loss of PGRN contributes to both FTD and NCL pathology in a dose-dependent manner.
AB - Frontotemporal dementia (FTD) encompasses a group of neurodegenerative disorders characterized by cognitive and behavioral impairments. Heterozygous mutations in progranulin (PGRN) cause familial FTD and result in decreased PGRN expression, while homozygous mutations result in complete loss of PGRN expression and lead to the neurodegenerative lysosomal storage disorder neuronal ceroid lipofuscinosis (NCL). However, how dose-dependent PGRN mutations contribute to these two different diseases is not well understood. Using iPSC-derived human cortical neurons from FTD patients harboring PGRN mutations, we demonstrate that PGRN mutant neurons exhibit decreased nuclear TDP-43 and increased insoluble TDP-43, as well as enlarged electron-dense vesicles, lipofuscin accumulation, fingerprint-like profiles and granular osmiophilic deposits, suggesting that both FTD and NCL-like pathology are present in PGRN patient neurons as compared to isogenic controls. PGRN mutant neurons also show impaired lysosomal proteolysis and decreased activity of the lysosomal enzyme cathepsin D. Furthermore, we find that PGRN interacts with cathepsin D, and that PGRN increases the activity of cathepsin D but not cathepsins B or L. Finally, we show that granulin E, a cleavage product of PGRN, is sufficient to increase cathepsin D activity. This functional relationship between PGRN and cathepsin D provides a possible explanation for overlapping NCL-like pathology observed in patients with mutations in PGRN or CTSD, the gene encoding cathepsin D. Together, our work identifies PGRN as an activator of lysosomal cathepsin D activity, and suggests that decreased cathepsin D activity due to loss of PGRN contributes to both FTD and NCL pathology in a dose-dependent manner.
UR - http://www.scopus.com/inward/record.url?scp=85042866298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042866298&partnerID=8YFLogxK
U2 - 10.1093/hmg/ddx364
DO - 10.1093/hmg/ddx364
M3 - Article
C2 - 29036611
AN - SCOPUS:85042866298
SN - 0964-6906
VL - 26
SP - 4861
EP - 4872
JO - Human molecular genetics
JF - Human molecular genetics
IS - 24
ER -